R Fleming, F Broekmans, C Calhaz-Jorge… - Reproductive …, 2013 - Elsevier
The ability to predict the response potential of women to ovarian stimulation may allow the development of individualized ovarian stimulation protocols. This tailored approach to …
JC Arce, A La Marca, BM Klein, AN Andersen… - Fertility and sterility, 2013 - Elsevier
OBJECTIVE: To assess the relationships between serum antimüllerian hormone (AMH) and ovarian response and treatment outcomes in good-prognosis patients undergoing controlled …
Objective This retrospective study determined for the first time the role of baseline antral follicle count (AFC) and serum anti-Mullerian hormone (AMH) level in the first in-vitro …
M Grynberg, A Pierre, R Rey, A Leclerc… - The Journal of …, 2012 - academic.oup.com
Background: Anti-Müllerian hormone (AMH) is a member of the TGF-β family, which limits follicle maturation. Recently serum AMH has been recognized as a useful diagnostic and …
Z Merhi, E Buyuk, DS Berger, A Zapantis… - Human …, 2013 - academic.oup.com
STUDY QUESTION Do the adipocytokines, leptin and adiponectin affect the granulosa cell expression of anti-Mullerian hormone (AMH) and its receptor (AMHR-II)? SUMMARY …
E Anckaert, J Smitz, J Schiettecatte… - Human …, 2012 - academic.oup.com
BACKGROUND This study evaluated the predictive value of serum and follicular fluid (FF) concentrations of anti-Müllerian hormone (AMH) with respect to treatment outcome variables …
O Hamdine, MJC Eijkemans, EWG Lentjes… - Human …, 2015 - academic.oup.com
STUDY QUESTION What is the clinical value of anti-Müllerian hormone (AMH) for the prediction of high or low ovarian response in controlled ovarian stimulation for IVF using …
L Melado, B Lawrenz, J Sibal, E Abu… - Frontiers in …, 2018 - frontiersin.org
Anti-Müllerian hormone (AMH) is an important ovarian reserve marker for baseline assessment and therapeutic strategy in fertility treatments, which is considered reliable …
LC Poulsen, AK Warzecha, NS Bülow… - Human …, 2022 - academic.oup.com
STUDY QUESTION What are the downstream endocrine and paracrine consequences of letrozole (LZ) cotreatment during ovarian stimulation and is follicle growth and recruitment …